Heska Corp (NASDAQ:HSKA) Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL lowered its position in shares of Heska Corp (NASDAQ:HSKA) by 8.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,000 shares of the medical research company’s stock after selling 3,000 shares during the quarter. Gamco Investors INC. ET AL owned approximately 0.40% of Heska worth $2,197,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new stake in shares of Heska in the third quarter valued at approximately $4,588,000. California Public Employees Retirement System grew its position in shares of Heska by 27.0% in the third quarter. California Public Employees Retirement System now owns 8,761 shares of the medical research company’s stock valued at $621,000 after purchasing an additional 1,863 shares in the last quarter. State of Tennessee Treasury Department grew its position in shares of Heska by 8.5% in the third quarter. State of Tennessee Treasury Department now owns 2,770 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 218 shares in the last quarter. SG Capital Management LLC purchased a new stake in shares of Heska in the third quarter valued at approximately $20,182,000. Finally, Rhumbline Advisers grew its position in shares of Heska by 2.1% in the third quarter. Rhumbline Advisers now owns 20,914 shares of the medical research company’s stock valued at $1,482,000 after purchasing an additional 440 shares in the last quarter. 92.57% of the stock is owned by institutional investors and hedge funds.

Heska stock traded up $0.93 during mid-day trading on Friday, hitting $91.58. The company’s stock had a trading volume of 74,900 shares, compared to its average volume of 89,917. Heska Corp has a 1 year low of $62.47 and a 1 year high of $105.00. The company has a current ratio of 8.52, a quick ratio of 2.05 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $735.22 million, a PE ratio of 64.49 and a beta of 1.06. The stock’s fifty day moving average is $75.74 and its two-hundred day moving average is $76.31.

Heska (NASDAQ:HSKA) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.04). Heska had a return on equity of 3.17% and a net margin of 3.15%. The company had revenue of $31.24 million for the quarter, compared to analysts’ expectations of $30.44 million. On average, equities analysts expect that Heska Corp will post 0.04 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on HSKA shares. Canaccord Genuity restated a “buy” rating and issued a $105.00 price target (up from $75.00) on shares of Heska in a research report on Wednesday. Raymond James lowered Heska from an “outperform” rating to a “market perform” rating in a research report on Thursday. They noted that the move was a valuation call. BidaskClub upgraded Heska from a “hold” rating to a “buy” rating in a research report on Thursday, October 31st. Piper Jaffray Companies started coverage on Heska in a research report on Wednesday, September 18th. They issued a “neutral” rating and a $68.00 price target for the company. Finally, Zacks Investment Research lowered Heska from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. Seven investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $85.75.

Heska Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Recommended Story: Discount Rate

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply